Metformin: its emerging role in oncology

Area of Science:

• Oncology
• Endocrinology
• Molecular Biology

Background:

• Metformin is a first-line treatment for type 2 diabetes mellitus (DM).
• Clinical studies suggest reduced cancer incidence in DM patients treated with metformin.
• In vitro studies indicate metformin possesses antiproliferative and proapoptotic properties against various cancers.

Purpose of the Study:

• To investigate the anti-cancer mechanisms of metformin.
• To explore the role of AMP-activated protein kinase (AMPK) and mammalian target of rapamycin complex 1 (mTORC1) signaling in metformin's effects.
• To highlight the potential of metformin as an adjunct cancer therapy.

Main Methods:

• Review of clinical and in vitro studies on metformin's effects on neoplastic diseases.
• Analysis of metformin's molecular targets, including AMPK, LKB1, and mTORC1.
• Examination of the AMPK/mTOR signaling pathway in cancer cell proliferation.

Main Results:

• Metformin activates AMP-activated protein kinase (AMPK) by inducing LKB1 (serine/threonine kinase 11).
• Activation of AMPK by metformin leads to the inhibition of mammalian target of rapamycin complex 1 (mTORC1).
• Inhibition of mTORC1 by metformin results in decreased cancer cell proliferation.

Conclusions:

• Metformin demonstrates promising anti-cancer effects through the AMPK/mTOR signaling pathway.
• Metformin's ability to activate tumor suppressor LKB1 and inhibit mTORC1 warrants further investigation.
• Clinical studies are crucial to establish metformin's role as a synergistic anti-cancer therapy.